

# 50 YEARS OF IMAGING INNOVATION

analogic



Q4 FY2017 EARNINGS CALL

SEPTEMBER 19, 2017



# Safe Harbor

Any statements about future expectations, plans, and prospects for the Company, including statements containing the words “believes,” “anticipates,” “plans,” “expects,” and similar expressions, constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including risks relating to product development and commercialization, limited demand for the Company’s products, risks associated with competition, uncertainties associated with regulatory agency approvals, competitive pricing pressures, downturns in the economy, the risk of potential intellectual property litigation, acquisition related risks, and other factors discussed in our most recent quarterly or annual report filed with the Securities and Exchange Commission. In addition, the forward-looking statements included in this presentation represent the Company’s views as of the date of this document. While the Company anticipates that subsequent events and developments will cause the Company’s views to change, the Company specifically disclaims any obligation to update these forward-looking statements. These forward-looking statements should not be relied upon as representing the Company’s views as of any later date.

# Use of Non-GAAP Financial Measures

This presentation includes non-GAAP financial measures that are not in accordance with, nor an alternative to, generally accepted accounting principles and may be different from such non-GAAP measures used by other companies. In addition, these non-GAAP measures are not based on any comprehensive set of accounting rules or principles.

Management uses non-GAAP gross margin, non-GAAP operating expenses, non-GAAP operating income, non-GAAP operating margin, non-GAAP net income and non-GAAP diluted earnings per share to evaluate the Company's operating performance against past periods and to budget and allocate resources in future periods. These non-GAAP measures also assist management in understanding and evaluating the underlying baseline operating results and trends in the Company's business.

With respect to forwarding looking measures, we provide an outlook for our non-GAAP operating margins and earnings. We do not provide operating margin or earnings outlook on a GAAP basis. Many of the items that we exclude from our Non-GAAP operating margin and earnings calculations, such as amortization of intangibles, acquisition related costs, restructuring expenses, and one-time tax adjustments, are less capable of being controlled or reliably predicted by management. These items could cause our GAAP operating margins and earnings to vary materially from the corresponding Non-GAAP figures presented in our outlook statements.

Non-GAAP financial measures should not be considered as a substitute for, or superior to, measures of financial performance prepared in accordance with GAAP. They are limited in value because they exclude charges that have a material effect on our reported results and, therefore, should not be relied upon as the sole financial measures to evaluate our financial results. The non-GAAP financial measures are meant to supplement, and to be viewed in conjunction with, GAAP financial measures. A reconciliation of GAAP to non-GAAP financial measures can be found in the appendix to this presentation and our Fourth Quarter FY2017 press release issued September 19, 2017 available at our website <http://investor.analogic.com>.

# Agenda

- Opening Comments – Fred Parks, President and CEO
- Quarterly Financial Results – Mike Bourque, SVP CFO and Treasurer
- Closing Comments and Outlook – Fred Parks, CEO
- Q&A

# Strategic Sale Process Underway

- Analogic Board of Directors is focused on maximizing shareholder value and believes that a sale of the company may create more certain value for shareholders
- Retained Citi as financial advisor and initiated a process for the sale of entire company
- Updates will be provided if and when appropriate

# FY17 Challenges Behind Us; FY18 Looks Brighter

- Completed restructuring and portfolio optimization for a profitable FY18
  - BK Ultrasound re-focused attention in core Urology and Surgery
  - \$24 million overall annual cost savings, impact to Q4 balance sheet
- Security on doorstep of significant growth
  - American Airlines placed initial PO for multiple ConneCT systems
  - ConneCT received U.S. TSA certification, EU pending
  - Rapid DNA Act signed into law allowing deployment
- Rebuilding Medical Imaging to historical levels by FY20
  - Shift in mix from components to full CT systems
  - MRI and Mammo technology refresh

# Q4 FY17 Financial Highlights

- Revenue \$112M, lower than expected on lower CT and revenue adjustments on engineering projects

- GAAP Gross Margin 34%

- GAAP Operating Margin -14%, Non-GAAP\* Operating Margin -4%


- GAAP EPS (\$1.98)

- Includes \$8.3 million, (\$0.42) per share, inventory impairment charges
- Includes \$4.8 million, (\$0.26) per share, restructuring charges
- Includes \$17.2 million, (\$1.38) per share, valuation allowance adjustment

- Non-GAAP\* EPS (\$0.00)

- Cash on hand plus liquid investments of \$174 million

Revenue and Non-GAAP\* EPS



\* Non-GAAP operating margin/income figures exclude certain charges; please refer to the non-GAAP reconciliation table in the back of this presentation and in Analogic's Q4 FY 2017 earnings release available at <http://investor.analogic.com>.

# Q4 FY17 Financial Results

(In millions, except per share data)

	GAAP		Non-GAAP	
	Three months ended July 31		Three months ended July 31	
	Q4 FY17	Q4 FY16	Q4 FY17	Q4 FY16
Products	\$ 112.8	\$ 136.3	\$ 113.0	\$ 136.4
Engineering	(1.2)	1.7	(1.2)	1.7
<b>Total Revenue</b>	<b>\$ 111.6</b>	<b>\$ 138.1</b>	<b>\$ 111.7</b>	<b>\$ 138.1</b>
<b>Gross Profit</b>	<b>37.8</b>	<b>63.4</b>	<b>38.5</b>	<b>64.4</b>
<b>Gross Margin</b>	<b>33.9%</b>	<b>45.9%</b>	<b>34.5%</b>	<b>46.6%</b>
Research & Development	16.5	16.9	16.1	16.3
Selling & Marketing	15.9	19.0	14.7	17.0
General & Administrative	15.1	12.1	12.5	11.3
Restructuring	4.8	1.4	-	-
Asset Impairment Charges	1.0	-	-	-
<b>Operating Expenses</b>	<b>53.4</b>	<b>49.3</b>	<b>43.3</b>	<b>44.7</b>
<b>Op Ex % of Revenue</b>	<b>47.8%</b>	<b>35.7%</b>	<b>38.7%</b>	<b>32.4%</b>
<b>Operating Income</b>	<b>(15.6)</b>	<b>14.1</b>	<b>(4.7)</b>	<b>19.7</b>
<b>Operating Margin</b>	<b>-14.0%</b>	<b>10.2%</b>	<b>-4.2%</b>	<b>14.3%</b>
Other Income (Expense)	0.9	0.0	0.9	0.0
<b>Income Before Taxes</b>	<b>(14.7)</b>	<b>14.1</b>	<b>(3.9)</b>	<b>19.7</b>
Income Tax Provision (Benefit)	9.9	5.3	(3.9)	7.0
<b>Effective tax rate</b>	<b>-67.4%</b>	<b>37.8%</b>	<b>100.5%</b>	<b>35.3%</b>
<b>Net Income</b>	<b>\$ (24.6)</b>	<b>\$ 8.8</b>	<b>\$ 0.0</b>	<b>\$ 12.8</b>
<b>Diluted EPS</b>	<b>\$ (1.98)</b>	<b>\$ 0.70</b>	<b>\$ -</b>	<b>\$ 1.02</b>

- GAAP Operating Expenses increased \$4.1M compared to Q4'16
  - Restructuring and Asset impairment charges up \$4M
  - G&A up \$3M on legal fees and headcount transition costs
  - Sales & Marketing down \$3M on headcount related savings
- Non-GAAP Operating Expenses decreased \$1.4M (\$2.6M excluding significant one-time charges)
  - Sales and Marketing down \$2.3M on headcount savings
  - G&A up \$1.1M on legal fees and headcount transition costs
- Non-GAAP Income tax rate is up 65.2 pts. compared to Q4'16 driven by a disproportionately large tax benefit in Q4'17 given the pre-tax losses and the effect of the GAAP valuation allowance being adjusted out for Non-GAAP reporting.

\* Non-GAAP operating margin/income figures exclude certain charges; please refer to the non-GAAP reconciliation table in the back of this presentation and in Analogic's Q4 FY 2017 earnings release available at <http://investor.analogic.com>.


(Amounts and percentages may not foot due to rounding to millions)




# Operating Performance by Segment

Revenue \$M and Non-GAAP\* Operating Margin Trend


## Medical Imaging



## Ultrasound



## Security & Detection



— Non-GAAP Operating Margin\*

- **Medical Imaging** revenue down 16% on lower CT and MRI offset by favorability in Mammography and Motion; non-GAAP op margin 16%.
- **Ultrasound** revenue down 21% on lower general imaging, revenue adjustment due to an engineering project, discontinued Oncura new equipment sales coupled with a challenging comp in North America partially offset by growth in Asia/China; non-GAAP op margin -34%
- **Security & Detection** revenue down 28% on revenue adjustment due to an engineering project and timing of 3DX and XLB shipments; non-GAAP op margin -25% on higher ConneCT R&D spend, asset impairment charges and revenue adjustment

\* Non-GAAP operating margin/income figures exclude certain charges; please refer to the non-GAAP reconciliation table in the back of this presentation and in Analogic's Q4 FY 2017 earnings release available at <http://investor.analogic.com>.

# Twelve Months FY17 Financial Results

(In millions, except per share data)

	GAAP		Non-GAAP	
	Twelve months ended July 31		Twelve months ended July 31	
	FY17	FY16	FY17	FY16
Products	\$ 484.2	\$ 502.8	\$ 484.8	\$ 503.2
Engineering	2.2	6.1	2.2	6.1
<b>Total Revenue</b>	<b>\$ 486.4</b>	<b>\$ 508.8</b>	<b>\$ 487.0</b>	<b>\$ 509.2</b>
<b>Gross Profit</b>	<b>199.3</b>	<b>228.1</b>	<b>203.0</b>	<b>232.3</b>
<b>Gross Margin</b>	<b>41.0%</b>	<b>44.8%</b>	<b>41.7%</b>	<b>45.6%</b>
Research & Development	63.5	67.1	61.7	64.9
Selling & Marketing	67.8	65.3	61.8	58.3
General & Administrative	43.1	60.8	47.0	45.6
Restructuring	7.2	9.6	-	-
Asset Impairment Charges	84.5	-	-	-
<b>Operating Expenses</b>	<b>266.1</b>	<b>202.9</b>	<b>170.6</b>	<b>168.8</b>
<b>Op Ex % of Revenue</b>	<b>54.7%</b>	<b>39.9%</b>	<b>35.0%</b>	<b>33.1%</b>
<b>Operating Income</b>	<b>(66.8)</b>	<b>25.2</b>	<b>32.4</b>	<b>63.5</b>
<b>Operating Margin</b>	<b>-13.7%</b>	<b>5.0%</b>	<b>6.7%</b>	<b>12.5%</b>
Other Income (Expense)	0.5	(4.9)	0.5	(1.7)
<b>Income Before Taxes</b>	<b>(66.3)</b>	<b>20.3</b>	<b>32.9</b>	<b>61.8</b>
Income Tax Provision (Benefit)	8.0	8.2	5.0	17.1
<b>Effective tax rate</b>	<b>-12.0%</b>	<b>40.3%</b>	<b>15.1%</b>	<b>27.6%</b>
<b>Net Income</b>	<b>\$ (74.2)</b>	<b>\$ 12.1</b>	<b>\$ 27.9</b>	<b>\$ 44.7</b>
<b>Diluted EPS</b>	<b>\$ (5.96)</b>	<b>\$ 0.96</b>	<b>\$ 2.22</b>	<b>\$ 3.54</b>

- GAAP Operating Expenses increased \$63.2M compared to YTD'16
  - R&D down \$3.6M on lower material expenses and headcount savings
  - G&A down \$17.8M due to prior year expenses related to the BK Distributor Matter, Oncura vet contingent consideration adjustments offset by one-timers
  - Restructuring down \$2.5M
  - Sales and Marketing up \$2.5M, related to Oncura vet spend
  - Asset impairments charges of \$84.5M
- Non-GAAP Operating Expenses increased \$1.7M;
  - R&D down \$3.2M on lower material and headcount savings
  - G&A up \$1.6M due to CEO transition expenses and higher legal fees
  - Sales and Marketing up \$3.5M, due primarily to Oncura vet spend

\* Non-GAAP operating margin/income figures exclude certain charges; please refer to the non-GAAP reconciliation table in the back of this presentation and in Analogic's Q4 FY 2017 earnings release available at <http://investor.analogic.com>.

(Amounts and percentages may not foot due to rounding to millions)

# Working Capital and Cash Flow

(Unaudited - in millions)

	Q4 FY17	Q4 FY16
<b>Cash and Cash Equivalents</b>	<b>\$ 129.3</b>	<b>\$ 118.7</b>
Accounts receivable	77.6	112.4
Inventories	130.6	145.5
Other Working Capital, Net	(33.9)	(66.3)
<b>Non-Cash Working Capital</b>	<b>174.3</b>	<b>191.6</b>
<b>Net Working Capital</b>	<b>\$ 303.6</b>	<b>\$ 310.3</b>
Cash and Cash Equivalents	\$ 129.3	\$ 118.7
ST-LT Investments	45.0	-
<b>Cash and Liquid Investments</b>	<b>\$ 174.3</b>	<b>\$ 118.7</b>

## Cash Flow

(Unaudited - in millions)

	YTD FY17	YTD FY16
Operating Cash Flow from operations	\$ 76.3	\$ 33.0
Capital Spending	9.1	13.1
<b>Free cash flow*</b>	<b>67.2</b>	<b>19.9</b>
Stock repurchased and dividends paid	9.4	18.7
<b>Cash flow after stock repurchase and dividends</b>	<b>\$ 57.8</b>	<b>\$ 1.2</b>

- **For FY17 - Operating cash flow** of \$76M, **Cap Ex** of \$9M resulting in **Free cash flow** of \$67M
- **Accounts receivables** down on lower revenues
- **Inventory** lower on write offs

\*Free cash flow is defined as operating cash flow minus capital expenditures

(Amounts may not foot due to rounding to millions)

# FY 2018 Outlook

*Ultrasound Returns to Profitability, Medical Imaging Short Term Challenges; Security shows Continued Strong Revenue Growth*

For FY 2018 we expect revenue between \$445 and \$460 million with non-GAAP operating margins of 10% to 11% delivering non-GAAP diluted EPS of between \$2.70 to \$2.90. Q1 of fiscal 2018 is expected to be lower than Q4 2017 with sequential improvement throughout the fiscal year

## **Ultrasound: Low-single digit non-GAAP operating margin on down mid-single digit revenue**

- Core growth in Urology / Surgery
- Lower annual operating expenses by \$20 million

## **Medical Imaging: Low-double digit revenue decline with mid-teens non-GAAP operating margins**

- CT OEM customer sourcing decisions partially offset by private label CT system growth in China
- MRI and Mammo down for the year with Motion Controls up
- Investment year for CT growth, and for MRI and Mammo technology refresh

## **Security and Detection: Double-digit revenue growth with mid-teens non-GAAP operating margin**

- Continued demand for medium speed and strong back-log for high speed systems
- TSA certification complete; ConneCT enters early phase of deployment
- Growth in Rapid DNA

# Q&A

# Appendix

# Reconciliation of Certain Non-GAAP Financial Measures

(In thousands, except per share data)

	Three Months Ended		Twelve Months Ended	
	July 31, 2017	July 31, 2016	July 31, 2017	July 31, 2016
<b>GAAP (Loss) Income From Operations</b>	\$ (15,565)	\$ 14,090	\$ (66,760)	\$ 25,213
Share-based compensation expense	3,076	1,720	9,431	8,797
Acquisition-related revenues and expenses	1,668	2,360	(2,204)	9,376
BK Medical distributor matter inquiry related costs	251	195	274	10,467
Restructuring	4,787	1,372	7,167	9,641
Asset impairment charges	1,036	-	84,510	-
<b>Non-GAAP Income From Operations</b>	<b>\$ (4,748)</b>	<b>\$ 19,737</b>	<b>\$ 32,420</b>	<b>\$ 63,494</b>
<b>GAAP Operating Margin</b>	-14.0%	10.2%	-13.7%	5.0%
Effect of non-GAAP adjustments	9.7%	4.1%	20.4%	7.5%
<b>Non-GAAP Operating Margin</b>	-4.2%	14.3%	6.7%	12.5%
<b>GAAP Other Income (Expense), net</b>	\$ 854	\$ 3	\$ 497	\$ (4,897)
BK Medical distributor matter inquiry related costs	-	-	-	3,211
<b>Non-GAAP Other Income (Expense), net</b>	<b>\$ 854</b>	<b>\$ 3</b>	<b>\$ 497</b>	<b>\$ (1,686)</b>
Percentage of Total Net Revenue	0.8%	0.0%	0.1%	-0.3%
<b>GAAP Tax Provision (Benefit)</b>	\$ 9,908	\$ 5,326	\$ 7,974	\$ 8,189
GAAP Tax Rate	-67.4%	37.8%	-12.0%	40.3%
<b>Non-GAAP Tax Provision (Benefit)</b>	(3,912)	6,963	\$ 4,966	\$ 17,080
Non-GAAP Tax Rate	100.5%	35.3%	15.1%	27.6%
<b>GAAP Net (Loss) Income</b>	\$ (24,619)	\$ 8,767	\$ (74,237)	\$ 12,127
Share-based compensation expense	2,111	1,121	6,421	6,029
Acquisition-related revenues and expenses	1,307	1,898	(97)	7,567
BK Medical distributor matter inquiry related costs	159	133	602	12,820
Restructuring	3,219	858	4,776	6,185
Asset impairment charges	657	-	73,301	-
Valuation Allowance Tax Effect	17,184	-	17,184	-
<b>Non-GAAP Net Income</b>	<b>\$ 18</b>	<b>\$ 12,777</b>	<b>\$ 27,950</b>	<b>\$ 44,728</b>
Percentage of Total Net Revenue	0.0%	9.3%	5.7%	8.8%
<b>GAAP Diluted EPS</b>	\$ (1.98)	\$ 0.70	\$ (5.96)	\$ 0.96
Effect of non-GAAP adjustments	1.98	0.32	8.18	2.58
<b>Non-GAAP Diluted EPS</b>	<b>\$ -</b>	<b>\$ 1.02</b>	<b>\$ 2.22</b>	<b>\$ 3.54</b>

(Amounts may not foot due to rounding to millions)

# Reconciliation of Certain Non-GAAP Financial Measures

(In thousands, except per share data)

	31-Oct-15	31-Jan-16	30-Apr-16	31-Jul-16	31-Oct-16	31-Jan-17	30-Apr-17	31-Jul-17
<b>GAAP Income (Loss) From Operations</b>	\$ 1,988	\$ 1,509	\$ 7,626	\$ 14,090	\$ 3,953	\$ 9,450	\$ (64,603)	\$ (15,565)
Share-based compensation expense	2,382	1,760	2,934	1,720	1,563	2,597	2,195	3,076
BK Medical distributor matter inquiry related costs	26	10,208	39	195	4	12	8	251
Restructuring	3,283	3,147	1,839	1,372	32	267	2,080	4,787
Acquisition-related revenues and expenses	2,061	2,492	2,462	2,360	2,212	(6,065)	(23)	1,668
Asset impairment charges	-	-	-	-	-	10,423	73,051	1,036
<b>Non-GAAP Income (Loss) From Operations</b>	\$ 9,740	\$ 19,116	\$ 14,900	\$ 19,737	\$ 7,764	\$ 16,684	\$ 12,708	\$ (4,748)
<b>GAAP Operating Margin</b>	1.7%	1.2%	6.0%	10.2%	3.3%	7.2%	-52.9%	-14.0%
Effect of non-GAAP adjustments	6.7%	13.8%	5.7%	4.1%	3.1%	5.5%	63.3%	9.7%
<b>Non-GAAP Operating Margin</b>	8.5%	14.9%	11.6%	14.3%	6.4%	12.7%	10.4%	-4.2%
<b>GAAP Other Income (Expense), net</b>	\$ (458)	\$ (3,507)	\$ (934)	\$ 3	\$ (442)	\$ 28	\$ 57	\$ 854
BK Medical distributor matter inquiry related costs	-	3,211	-	-	-	-	-	-
<b>Non-GAAP Other Income (Expense), net</b>	\$ (458)	\$ (296)	\$ (934)	\$ 3	\$ (442)	\$ 28	\$ 57	\$ 854
Percentage of Total Net Revenue	0%	0%	-1%	0%	0%	0%	0%	1%
<b>GAAP Net Income (Loss)</b>	\$ 1,376	\$ (2,985)	\$ 4,970	\$ 8,767	\$ 2,531	\$ 7,510	\$ (59,664)	\$ (24,619)
Share-based compensation expense	1,684	1,228	1,996	1,121	1,066	1,791	1,453	2,111
BK Medical distributor matter inquiry related costs	17	12,640	30	133	2	8	433	159
Restructuring	2,171	2,010	1,146	858	21	169	1,367	3,219
Acquisition related revenues, expenses and loss	1,722	1,989	1,958	1,898	1,752	(3,500)	338	1,307
Asset impairment charges	-	-	-	-	-	6,610	66,035	657
Valuation Allowance Tax Effect	-	-	-	-	-	-	-	17,184
<b>Non-GAAP Net Income</b>	\$ 6,969	\$ 14,882	\$ 10,100	\$ 12,777	\$ 5,372	\$ 12,588	\$ 9,962	\$ 18
Percentage of Total Net Revenue	6%	12%	8%	9%	4%	10%	8%	0%
<b>GAAP Diluted EPS</b>	\$ 0.11	\$ (0.24)	\$ 0.40	\$ 0.70	\$ 0.20	\$ 0.59	\$ (4.78)	\$ (1.98)
Effect of non-GAAP adjustments	0.44	1.43	0.40	0.32	0.23	0.40	5.57	1.98
<b>Non-GAAP Diluted EPS</b>	\$ 0.55	\$ 1.18	\$ 0.80	\$ 1.02	\$ 0.43	\$ 0.99	\$ 0.79	\$ -

(Amounts may not foot due to rounding to millions)



# Reconciliation of Certain Non-GAAP Segment Financial Measures

(in thousands, except per share data)

Three Months Ended

	31-Oct-15	31-Jan-16	30-Apr-16	31-Jul-16	31-Oct-16	31-Jan-17	30-Apr-17	31-Jul-17
<b>Medical Imaging</b>								
<b>GAAP Income (Loss) from Operations</b>	\$ 6,249	\$ 11,636	\$ 10,198	\$ 13,403	\$ 6,722	\$ 12,339	\$ 12,223	\$ 6,668
Share-based compensation expense	1,054	708	1,394	779	889	1,424	1,255	1,789
Restructuring	1,975	1,830	920	903	20	85	238	1,059
Acquisition related expenses	749	981	774	745	733	733	733	733
<b>Non-GAAP Income (Loss) From Operations</b>	<b>\$ 10,027</b>	<b>\$ 15,155</b>	<b>\$ 13,285</b>	<b>\$ 15,829</b>	<b>\$ 8,363</b>	<b>\$ 14,581</b>	<b>\$ 14,448</b>	<b>\$ 10,249</b>
Percentage of Total Net Revenue	15%	21%	18%	20%	12%	20%	21%	16%
<b>Ultrasound</b>								
<b>GAAP Income (Loss) from Operations</b>	\$ (4,421)	\$ (9,938)	\$ (4,938)	\$ (860)	\$ (5,807)	\$ (4,568)	\$ (79,354)	\$ (18,151)
Share-based compensation expense	744	522	830	513	415	745	549	746
BK Medical distributor matter inquiry related costs	26	10,208	39	195	4	12	8	251
Restructuring	735	786	652	207	6	172	1,758	3,572
Acquisition related revenues and expenses	1,178	1,410	1,647	1,582	1,428	(6,815)	(756)	934
Asset impairment charges	-	-	-	-	-	9,811	73,051	236
<b>Non-GAAP Income (Loss) From Operations</b>	<b>\$ (1,739)</b>	<b>\$ 2,987</b>	<b>\$ (1,770)</b>	<b>\$ 1,636</b>	<b>\$ (3,954)</b>	<b>\$ (643)</b>	<b>\$ (4,743)</b>	<b>\$ (12,411)</b>
Percentage of Total Net Revenue	-4%	7%	-5%	4%	-11%	-2%	-14%	-35%
<b>Security &amp; Detection</b>								
<b>GAAP Income (Loss) from Operations</b>	\$ 160	\$ (189)	\$ 2,366	\$ 1,547	\$ 3,038	\$ 1,679	\$ 2,528	\$ (4,083)
Share-based compensation expense	584	530	711	428	259	428	391	540
Restructuring	573	531	267	262	6	10	84	156
Acquisition related expenses	35	102	42	33	52	17	-	-
Asset impairment charges	-	-	-	-	-	612	-	800
<b>Non-GAAP Income (Loss) From Operations</b>	<b>\$ 1,352</b>	<b>\$ 974</b>	<b>\$ 3,386</b>	<b>\$ 2,271</b>	<b>\$ 3,355</b>	<b>\$ 2,746</b>	<b>\$ 3,003</b>	<b>\$ (2,587)</b>
Percentage of Total Net Revenue	10%	9%	19%	16%	18%	15%	17%	-25%
<b>Analogic</b>								
<b>GAAP Income (Loss) from Operations</b>	\$ 1,988	\$ 1,509	\$ 7,626	\$ 14,090	\$ 3,953	\$ 9,450	\$ (64,603)	\$ (15,565)
Share-based compensation expense	2,382	1,760	2,934	1,720	1,563	2,597	2,195	3,076
BK Medical distributor matter inquiry related costs	26	10,208	39	195	4	12	8	251
Restructuring	3,283	3,147	1,839	1,372	32	267	2,080	4,787
Acquisition related gains and expenses	2,062	2,492	2,462	2,360	2,212	(6,065)	(23)	1,667
Asset impairment charges	-	-	-	-	-	10,423	73,051	1,036
<b>Non-GAAP Income (Loss) From Operations</b>	<b>\$ 9,741</b>	<b>\$ 19,116</b>	<b>\$ 14,900</b>	<b>\$ 19,736</b>	<b>\$ 7,764</b>	<b>\$ 16,684</b>	<b>\$ 12,708</b>	<b>\$ (4,748)</b>
Percentage of Total Net Revenue	8%	15%	12%	14%	6%	13%	10%	-4%

(Amounts may not foot due to rounding to millions)

